MARKET WIREYahoo Finance • 13h ago
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026Yahoo Finance report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
Why ELUT Stock surged +2.89% Today — RQD Quant Desk Flash
$0.84 +2.89% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.84
Elutia Inc. (Class A) (ELUT) receives a Roarable Rating of E (Strong Sell) and flashes a Red SELL / AVOID rating (31/100 RQD Confidence). Alongside weak composite pillar scores, our SEC filing scanner spotted paper earnings outpacing operating cash flow (+296.7% (NI vs OCF)).
ROARABLE E • RED ALERT
Cap $36.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ELUT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ELUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Elutia Inc. (Class A) (NASDAQ: ELUT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.84 (+2.89% 1D, market cap $36.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 7/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ELUT compare to EXOZ and ESLA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELUT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 53.7%, and ROIC of -35.0%. By comparison, EXOZ (eXoZymes Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $38.2M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, ELUT leads on earnings multiple (N/A) while ELUT leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ELUT?
▼
Per ELUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708527), Elutia Inc. (Class A) generated $12.3M in revenue (-15.0% YoY), $53.4M in net income, and -$46.7M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.84 (+0.33%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELUT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY ELUT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (32% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (23% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.79+2.5% Next Q
23
Q2 (-2Q)Grade E$0.81-1.2% Next Q
26
Q3 (-1Q)Grade E$0.80+5% Next Q
28
CurrentGrade E$0.84-9.4% Hist 90D α
31
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ELUT Turnaround Squeeze
While ELUT currently carries a cautious 31/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.83) and Max Pain ($0.88) forces dealer call-delta covering toward $1.45.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELUT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ELUT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ELUT Stock surged +2.89% Today — RQD Quant Desk Flash
Elutia Inc. (Class A) (ELUT) surged +2.89% to $0.84, trading at 39% of its 52-week range ($0.5 – $1.38). Weak 31/100 RQD score compounded by SEC accrual divergence (+296.7% (NI vs OCF)).
- ▸Technical Tape: Trading at 39% of its 52-week range ($0.5 – $1.38) with RSI-14 at 48.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.84 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: ELUT Accounting Gap: Net Income (+198.9%) Outpaced OCF (-97.8%) With +65.6% Working-Capital Build
Live ELUT Headlines & Catalysts
MARKET WIRETradingView • 16h ago
Elutia, Inc. Estimates – BOATS:ELUTTradingView report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance UK • 19h ago
Elutia Inc. (ELUT) Seasonal returns chartYahoo Finance UK report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 32d ago
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan fa
RISK WATCHYahoo Finance • 53d ago
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15thGAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Office
MARKET WIREYahoo Finance • 61d ago
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment ConferenceGAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Office
CATALYSTYahoo Finance • 74d ago
Elutia (ELUT) Q2 2026 Earnings Call TranscriptCEO Mills reports 96% surgeon interest in NXT-41x platform ahead of late 2026 FDA clearance.
MARKET WIREYahoo Finance • 76d ago
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial LaunchDeal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 monthsDivestiture further concentrates Elutia’s attention and resources on the develop
MARKET WIREYahoo Finance • 80d ago
Elutia Inc. Q2 2026 Earnings Call SummaryMoby summary of Elutia Inc.'s Q2 2026 earnings call
CATALYSTYahoo Finance • 81d ago
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ...Elutia Inc (ELUT) reports Q2 2026 results, highlighting robust surgeon interest in NXT41X and a strengthened balance sheet despite a slight revenue dip.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELUT)
- ✓Walkthrough of ELUT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ELUT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.83%⚡ TESTING RESISTANCE
2026-11-02O $0.84H $0.84L $0.81C $0.84VOL 56.0K
RES: $0.87SUP: $0.61SMA50: $0.83SMA200: $0.97
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ELUT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ELUT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ELUT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ELUT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELUT)
Health Care Rank #822 of 1016
⚔️ EXOZ vs ELUT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ELUT vs. EXOZ, ESLA, ALGS, MGX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Elutia Inc. (Class A) (ELUT) ranks #822 by composite RQD confidence (31/100, grade E) and #786 by equity capitalization ($36.0M). Within this direct 5-issuer industry benchmark cohort, ELUT leads on earnings valuation at N/A trailing P/E, while ELUT leads on capital efficiency and profitability with -35.0% ROIC and 53.7% gross margin. ESLA currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with ELUT at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELUT
ACTIVE
Elutia Inc. (Class A) | E | 31/100 | — | 53.7% | -35.0% | +2.89% | $36.0M | Benchmark Subject |
| EXOZ eXoZymes Inc. | E | 32/100 | — | — | -35.0% | +0.49% | $38.2M | /exoz-vs-elut → |
| ESLA Estrella Immunopharma Inc. | D- | 39/100 | — | — | -35.0% | -12.27% | $31.7M | /esla-vs-elut → |
| ALGS Aligos Therapeutics Inc. | E | 22/100 | — | — | -35.0% | -4.57% | $31.4M | /algs-vs-elut → |
| MGX Metagenomi Therapeutics Inc. | E | 24/100 | — | — | -35.0% | -6.01% | $31.4M | /mgx-vs-elut → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001708527In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elutia Inc. (Class A) (ELUT) reported GAAP revenue of $12.3M (-15.0% vs. FY2024 revenue of $14.5M ) , GAAP net income of $53.4M, operating cash flow of -$44.8M, and free cash flow of -$46.7M (-100.3% YoY). On the balance sheet, ELUT closed FY2025 with $62.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $12.3M | $53.4M | -$44.8M | -$46.7M | $62.4M | — |
| FY2024 (FY) | 2024-12-31 | $14.5M | -$53.9M | -$22.7M | -$23.3M | $36.1M | $22.6M |
| FY2023 (FY) | 2023-12-31 | $0 | -$37.7M | -$21.8M | -$21.8M | — | — |
3. ELUT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ELUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Elutia Inc. (Class A) (NASDAQ: ELUT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.84 (+2.89% 1D, market cap $36.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 7/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.
How does ELUT compare to EXOZ and ESLA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELUT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 53.7%, and ROIC of -35.0%. By comparison, EXOZ (eXoZymes Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $38.2M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, ELUT leads on earnings multiple (N/A) while ELUT leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ELUT?
Per ELUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708527), Elutia Inc. (Class A) generated $12.3M in revenue (-15.0% YoY), $53.4M in net income, and -$46.7M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ELUT trading relative to its 50-day, 200-day, and 52-week technical levels?
ELUT last traded at $0.84 (+2.89% on volume of 138,310 shares), positioning the stock +1.20% above its 50-day simple moving average ($0.83) and -13.40% below its 200-day simple moving average ($0.97). Across its 52-week range of $0.50 to $1.38, ELUT sits at the 38.6% percentile with a 14-day RSI of 48.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.94).
ELUT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ELUT stock moving today?
Why ELUT Stock surged +2.89% Today — RQD Quant Desk Flash. Weak 31/100 RQD score compounded by SEC accrual divergence (+296.7% (NI vs OCF)).
ROARABLE RATING BRIEF • RQD 31/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ELUT — Elutia Inc. (Class A): What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:48:10Z
Roarable Rating Brief: What This Means to a Prospective Investor
The per the Roarable RQD rating, ELUT scores 31 out of 100 and carries a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
- Fundamental Cash Engine (0 / 20): ROIC of -35% and FCF yield of 0%. This pillar contributes nothing to the score, meaning the core operating economics are not currently generating returns on capital or free cash.
- Whale 13F Flow (10 / 20): Institutional accumulation and options positioning are described as partially supportive, but the source does not itemize holder data (see Analyst View section).
- Insider Conviction (7 / 20): SEC Form 4 and Congressional PTR cluster flow are scored at a low level, indicating limited insider signal strength.
- Macro Regime Fit (7 / 20): Beta of 1.0 and sector sensitivity are scored modestly.
- Forensic Balance Sheet (7 / 20): Altman Z of 0.2, Piotroski F of 4/9, and Debt/Equity of 0.5 combine to a weak forensic profile.
For a prospective investor evaluating the stock today, the implication is that the rating signals elevated downside risk. The zero score on cash-generation metrics means the valuation case rests on factors outside current cash returns. Upside would require a meaningful shift in operating cash generation, which the rating does not currently show. The forensic balance-sheet pillar further suggests financial distress risk. Investors should treat this as a high-risk, forensically weak profile rather than a stable value candidate.
Business
Elutia Inc. (Class A) (ELUT) is a NASDAQ-listed issuer. Per the profile, it operates in the Health Care sector, specifically Biotechnology: Biological Products (No Diagnostic Substances). The source data does not describe its products, customers, or specific revenue model. Per the profile, its market capitalization is $0.0B, which conflicts with the $36.0M shown in market data; the profile figure is rounded to zero billions. Not available in source data for product or customer detail.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $12.3M | $-26.9M | $53.4M | N/A | $-46.7M | $36.4M | N/A |
| FY 2024 | $14.5M | $-30.7M | $-53.9M | N/A | $-23.3M | $13.2M | $22.6M |
| FY 2023 | $0.0M | $-30.5M | $-37.7M | N/A | $-21.8M | N/A | N/A |
Per the SEC financials, operating income was negative in all three reported periods, and free cash flow was negative throughout. FY 2025 shows net income of $53.4M against operating income of $-26.9M, a divergence the source does not explain. Per the market data, gross margin is 53.7%, operating margin is -60%, and net margin is 68%. The Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9, both per the Roarable RQD rating. Debt/Equity is 0.5 per the same source. Balance sheet posture appears strained, with cash of $36.4M against negative free cash flow.
Recent Catalysts & News Wire Analysis
- Catalyst: Elutia is scheduled to report third-quarter 2026 financial results on Thursday, November 5, 2026 (per the news wire, Yahoo Finance).
- Market wire items: Three news items from Yahoo Finance, TradingView, and Yahoo Finance UK were flagged as "MARKET WIRE" with YELLOW light; the summaries are generic and contain no substantive fundamental detail.
- Proprietary signal (Butterfly Graph): An Accrual & Working Capital Watch with severity 92 and a BEARISH direction. Per the graph, net income growth of +198.9% diverged from operating cash flow growth of -97.8%, with a +296.7% cash conversion gap and non-cash current assets and receivables up +65.6% relative to revenue growth. The graph advises monitoring the upcoming 10-Q for cash realization.
Open Questions
- What explains FY 2025 net income of $53.4M when operating income was $-26.9M, and is it a one-time or non-operating item?
- What is the company's debt position in FY 2025, given debt is listed as N/A for that period?
- What are Elutia's products, commercial traction, and revenue sources?
- Will the Q3 2026 10-Q confirm or reverse the accrual and working-capital divergence flagged by the Butterfly Graph?
- What is the source of the discrepancy between the $0.0B profile market cap and the $36.0M market data figure?
ELUT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Elutia Inc. (Class A) (ELUT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 13h ago
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 Yahoo Finance report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 16h ago
Elutia, Inc. Estimates – BOATS:ELUT TradingView report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 19h ago
Elutia Inc. (ELUT) Seasonal returns chart Yahoo Finance UK report covering Elutia Inc. (Class A) (ELUT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 32d ago
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan fa
🔴 RISK WATCH Yahoo Finance • 53d ago
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Office
🟡 MARKET WIRE Yahoo Finance • 61d ago
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Office
🟢 CATALYST Yahoo Finance • 74d ago
Elutia (ELUT) Q2 2026 Earnings Call Transcript CEO Mills reports 96% surgeon interest in NXT-41x platform ahead of late 2026 FDA clearance.
🟡 MARKET WIRE Yahoo Finance • 76d ago
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 monthsDivestiture further concentrates Elutia’s attention and resources on the develop
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ELUT Bull vs. Bear Conversation Board — What's Your Call at $0.84?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELUT 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $0.71 (-12.3%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ELUT (E • RQD 31/100) a Buy at $0.81?
Welcome to the ELUT (Elutia Inc. (Class A)) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.63 (-22.2%)
Spot @ $0.81 Pump the brakes on ELUT — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ELUT, but look at what you are paying: current EV/EBITDA multiples with 53.7% gross margins. Unless Elutia Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $0.93 (+14.8%)
Spot @ $0.81 ELUT cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ELUT, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.81 (52-wk range $0.50 - $1.38), any beat on forward guidance forces shorts and underweight funds to chase.